SE445708B - Farmaceutiskt preparat innehallande ett kinazolinon och 5-klor-4-(2-imidazolin-2-yl-amino)-2,1,3-bensotiadiazol - Google Patents
Farmaceutiskt preparat innehallande ett kinazolinon och 5-klor-4-(2-imidazolin-2-yl-amino)-2,1,3-bensotiadiazolInfo
- Publication number
- SE445708B SE445708B SE8002642A SE8002642A SE445708B SE 445708 B SE445708 B SE 445708B SE 8002642 A SE8002642 A SE 8002642A SE 8002642 A SE8002642 A SE 8002642A SE 445708 B SE445708 B SE 445708B
- Authority
- SE
- Sweden
- Prior art keywords
- active
- active substance
- quinazolinone
- chloro
- imidazolin
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 3
- -1 2-IMIDAZOLIN-2-YL-AMINO Chemical class 0.000 title description 6
- 239000013543 active substance Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000011737 fluorine Chemical group 0.000 claims description 5
- 229910052731 fluorine Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- ZWOUXWWGKJBAHQ-UHFFFAOYSA-N fluproquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 ZWOUXWWGKJBAHQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003274 myotonic effect Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- RCFLBBHULHAKQU-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2h-pyridin-4-yl]-1h-benzimidazol-2-one;2-hydroxypropane-1,2,3-tricarboxylic acid;n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1.C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RCFLBBHULHAKQU-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101100387923 Caenorhabditis elegans dos-1 gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH340979 | 1979-04-10 | ||
| CH341179A CH640415A5 (en) | 1979-04-10 | 1979-04-10 | Therapeutic preparations for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8002642L SE8002642L (sv) | 1980-10-11 |
| SE445708B true SE445708B (sv) | 1986-07-14 |
Family
ID=25692937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8002642A SE445708B (sv) | 1979-04-10 | 1980-04-08 | Farmaceutiskt preparat innehallande ett kinazolinon och 5-klor-4-(2-imidazolin-2-yl-amino)-2,1,3-bensotiadiazol |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4442084A (it) |
| AR (1) | AR228255A1 (it) |
| AU (1) | AU538643B2 (it) |
| CA (1) | CA1147261A (it) |
| DE (1) | DE3012837A1 (it) |
| ES (1) | ES490453A0 (it) |
| FR (1) | FR2453648A1 (it) |
| GB (1) | GB2047534B (it) |
| HU (1) | HU183119B (it) |
| IE (1) | IE49676B1 (it) |
| IL (1) | IL59786A (it) |
| IT (1) | IT1143133B (it) |
| MY (1) | MY8500127A (it) |
| NL (1) | NL8002041A (it) |
| NZ (1) | NZ193379A (it) |
| PH (1) | PH17681A (it) |
| PT (1) | PT71066A (it) |
| SE (1) | SE445708B (it) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499991A1 (fr) * | 1981-02-19 | 1982-08-20 | Sandoz Sa | Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments |
| GB8306473D0 (en) * | 1983-03-09 | 1983-04-13 | Sandoz Ltd | Analgesic preparations |
| GB2135884B (en) * | 1983-03-09 | 1986-09-17 | Sandoz Ltd | Analgesic preparations containing tizanidine and paracetamol |
| JPS608274A (ja) * | 1983-06-27 | 1985-01-17 | Fujisawa Pharmaceut Co Ltd | 新規キナゾリノン誘導体およびその製造法・並びに抗アレルギ−剤 |
| HUT47849A (en) * | 1986-11-03 | 1989-04-28 | Sandoz Ag | Process for producing new pharmaceutical with analgetic and hypertonicity-relaxing effect |
| DE3738844A1 (de) * | 1987-11-16 | 1989-05-24 | Merck Patent Gmbh | Analgetikum |
| US5039999A (en) * | 1990-06-26 | 1991-08-13 | Hewlett-Packard Company | Accumulator and pressure control for ink-ket pens |
| DE10146275A1 (de) | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG16442A3 (bg) * | 1967-10-30 | 1972-11-20 | Max Denzer | Метод за получаване на нови о-изопропиламинобензофенони |
| CH569722A5 (it) * | 1971-06-24 | 1975-11-28 | Sandoz Ag | |
| US3759920A (en) * | 1971-06-24 | 1973-09-18 | Sandoz Ag | Process for the preparation of 1-substituted-phenyl-2(1h)-quinazolinones |
| BE801898A (en) * | 1973-07-04 | 1974-01-04 | Merck Patent Gmbh | Insomnia treatment - with synergistic mixt of carisoprodol and methaqualone |
-
1980
- 1980-04-02 DE DE19803012837 patent/DE3012837A1/de not_active Withdrawn
- 1980-04-03 GB GB8011256A patent/GB2047534B/en not_active Expired
- 1980-04-08 NL NL8002041A patent/NL8002041A/nl not_active Application Discontinuation
- 1980-04-08 IT IT48364/80A patent/IT1143133B/it active
- 1980-04-08 PT PT71066A patent/PT71066A/pt unknown
- 1980-04-08 SE SE8002642A patent/SE445708B/sv not_active IP Right Cessation
- 1980-04-08 HU HU80834A patent/HU183119B/hu not_active IP Right Cessation
- 1980-04-08 AU AU57223/80A patent/AU538643B2/en not_active Ceased
- 1980-04-09 FR FR8007936A patent/FR2453648A1/fr active Granted
- 1980-04-09 CA CA000349456A patent/CA1147261A/en not_active Expired
- 1980-04-09 IE IE724/80A patent/IE49676B1/en unknown
- 1980-04-09 NZ NZ193379A patent/NZ193379A/en unknown
- 1980-04-09 IL IL59786A patent/IL59786A/xx unknown
- 1980-04-10 AR AR280632A patent/AR228255A1/es active
- 1980-04-10 ES ES490453A patent/ES490453A0/es active Granted
- 1980-04-10 PH PH23883A patent/PH17681A/en unknown
-
1982
- 1982-08-11 US US06/407,153 patent/US4442084A/en not_active Expired - Fee Related
-
1985
- 1985-12-30 MY MY127/85A patent/MY8500127A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT1143133B (it) | 1986-10-22 |
| US4442084A (en) | 1984-04-10 |
| ES8105148A1 (es) | 1981-05-16 |
| AU538643B2 (en) | 1984-08-23 |
| IT8048364A0 (it) | 1980-04-08 |
| PT71066A (en) | 1980-05-01 |
| FR2453648B1 (it) | 1983-06-24 |
| HU183119B (en) | 1984-04-28 |
| MY8500127A (en) | 1985-12-31 |
| PH17681A (en) | 1984-11-02 |
| GB2047534A (en) | 1980-12-03 |
| IE49676B1 (en) | 1985-11-27 |
| SE8002642L (sv) | 1980-10-11 |
| AR228255A1 (es) | 1983-02-15 |
| AU5722380A (en) | 1980-10-16 |
| ES490453A0 (es) | 1981-05-16 |
| GB2047534B (en) | 1983-04-20 |
| IL59786A0 (en) | 1980-06-30 |
| NL8002041A (nl) | 1980-10-14 |
| DE3012837A1 (de) | 1980-10-30 |
| IL59786A (en) | 1984-02-29 |
| IE800724L (en) | 1980-10-10 |
| CA1147261A (en) | 1983-05-31 |
| FR2453648A1 (fr) | 1980-11-07 |
| NZ193379A (en) | 1984-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2175385T5 (es) | Combinacion farmaceutica que contiene un compuesto que tiene actividad antagonista de angiotensina ii y un compuesto que aumenta la sensibilidad a la insulina. | |
| ES2288631T3 (es) | Nuevo ligando ppar que no causa retencion de fluidos, edema o insuficiencia cardiaca congestiva. | |
| US20110172251A1 (en) | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| JPH07509456A (ja) | ２型糖尿病および肥満の治療および予防のための１，３−ジシクロプロピメチル−８−アミノ−キサンチンの使用 | |
| SE445708B (sv) | Farmaceutiskt preparat innehallande ett kinazolinon och 5-klor-4-(2-imidazolin-2-yl-amino)-2,1,3-bensotiadiazol | |
| Wauquier et al. | Effects of chlorpheniramine, pyrilamine and astemizole on intracranial self-stimulation in rats | |
| EP0351733B1 (en) | Use of 2,3,4,5-tetrahydro-1H-3-benzazepines in the treatment of neurological disorders | |
| CA2601509A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| US4208417A (en) | Indole derivatives and their use as anxiolytics | |
| SK15472001A3 (sk) | Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie | |
| EP0345931B1 (en) | Certain paf antagonist/antihistamine combinations and methods | |
| EP2146714B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| ITRM940322A1 (it) | "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione ed applicazione". | |
| JPH0240665B2 (it) | ||
| US5334592A (en) | Certain PAF antagonist antihistamine combinations and methods | |
| US20060025448A1 (en) | Hair growth stimulators | |
| EP0437025A2 (en) | Compositions containing aldose reductase inhibitors for the treatment of ulcers | |
| SK227092A3 (en) | Pharmaceutical agent against the high blood pressure | |
| US4333945A (en) | Thiazoline and imidazoline derivatives useful as minor tranquilizers | |
| FR2882931A1 (fr) | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique | |
| KR960005145B1 (ko) | 고혈압 및 울혈성 심부전증 치료용 약학적 조성물 | |
| NL9000158A (nl) | Samenstelling van benazepril/thiazidediureticum in lage dosering. | |
| US4329354A (en) | Thiazoline and imidazoline derivatives useful as antidepressants | |
| CA1331568C (en) | Pharmaceutical composition containing dihydropyridine-dianhydrohexitol and nitro derivative | |
| JP4344532B2 (ja) | 鼻炎用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8002642-0 Effective date: 19911108 Format of ref document f/p: F |